SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Unilateral Vestibulopathy (AUV)
Conditions
Acute Unilateral Vestibulopathy (AUV)
Trial Timeline
Aug 16, 2017 → Oct 15, 2019
NCT ID
NCT03110458About SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet
SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet is a phase 2 stage product being developed by Sensorion for Acute Unilateral Vestibulopathy (AUV). The current trial status is completed. This product is registered under clinical trial identifier NCT03110458. Target conditions include Acute Unilateral Vestibulopathy (AUV).
What happened to similar drugs?
20 of 20 similar drugs in Acute Unilateral Vestibulopathy (AUV) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03110458 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Unilateral Vestibulopathy (AUV)